Friday, October 23, 2026
08:30-08:40 (CET) Welcome and Current vision.
Co-Chairmen: Dror Mevorach and Arnon Nagler
08:40-09:55 Session 1: From haemato-oncology to autoimmunity
08:40-09:05 Current European guidelines for HSCT and CAR T in autoimmune diseases
Raffaella Greco, Milan
09:05-09:30 Safety in CAR T and bispecific antibodies in autoimmunity
Melanie Hagen, Erlangen
09:30-09:55 In-vivo CAR T for treatment of autoimmune diseases
Zhu Chen, Hefei
09:55-10:45 Session 2: Myositis spectrum
09:55-10:20 Myositis: How do you choose the right patient for Cellular and Humoral Therapy?
Ingrid Lundberg, Karolinska
10:20-10:45 Real-world data on TCEs in MDA5+ dermatomyositis
Runci Wang, Shanghai
10:45-12:30 Session 3: SLE, Antiphospholipid syndrome and additional autoimmune diseases
10:45-11:10 SLE revisited
William Robinson, Stanford
11:10-11:40 Antiphospholipid syndrome, a novel opportunity?
Dror Mevorach, Hebrew University
11:40-12:05 B cell targeting in autoimmune liver diseases
Richard Taubert, Hannover
12:05-12:30 CAR T CD19: A single academic center experience in autoimmunity
Merav Lidar, Tel-Aviv
12:30-13:15 Discussion (live): Dror Mevorach, Arnon Nagler and speakers